Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) announced that data from its Phase 3 pHalcon-NERD-301 trial has been published in the American ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE